Shattuck Labs, Inc.
Close on Oct 19, 2026
- Market cap
- $696.91M
- P/E (TTM)
- –
- Dividend yield
- –
About Shattuck Labs
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. It specializes in protein engineering to discover and advance monoclonal and bispecific antibodies that target the Death Receptor 3 (DR3) pathway. Its lead investigational product candidate is SL-325, a DR3-blocking monoclonal antibody intended to treat conditions such as inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. In addition, the pipeline includes SL-425, an extended half-life version of its primary candidate, alongside multiple preclinical bispecific antibodies designed to simultaneously inhibit DR3 and other biologically relevant disease pathways.
The business operates as a research and clinical-stage development enterprise without commercialized products or proprietary manufacturing plants. It contracts bulk drug substance production to a single third-party contract development and manufacturing organization, Kemwell Biopharma Private Limited. The provided text does not disclose the company's specific headquarters location, overall employee headcount, founding details, or official corporate website.
Summary of the business section of Shattuck Labs's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Shattuck Labs, Inc.
- Headquarters
- Austin, TX
- Address
- 500 W. 5th Street 78701
- Phone
- (512) 900-4690
- Employees
- 40, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Austin, TX, USA
Stock & identifiers
- Ticker
- STTK
- Exchange
- Nasdaq
- IPO date
- Oct 13, 2020
- Shares outstanding
- 100M, Aug 7, 2026
- Public float
- $22.83M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1680367
- CUSIP
- 82024L103
- ISIN
- US82024L1035
- EIN
- 81-2575858
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Taylor Schreiber | Chief Executive Officer, Director | 2,732,972 |
| Abhinav A. Shukla | Chief Technical Officer | 98,533 |
| Arundathy N. Pandite | Chief Medical Officer | 136,219 |
| Stephen Stout | See Remarks | 93,366 |
| Andrew R. Neill | Chief Financial Officer | 292,251 |
| Casi DeYoung | Chief Business Officer | 73,480 |
| Genesis GP LLC OrbiMed | Director | 1,051,021 |
| Advisors Llc Orbimed | Director | 5,255,106 |
| Mona Ashiya | Director | 5,255,106 |
| Capital GP IX LLC OrbiMed | Director | 1,051,021 |
| Clay B. Siegall | Director | 318,608 |
| Helen M. Boudreau | Director | – |
| George Golumbeski | Director | 54,613 |
| Daniel G. Baker | Director | – |
| Neil W. Gibson | Director | 52,745 |
| Jeremy Green | Director | 5,406,353 |
| Redmile Group, LLC | Director | 5,615,489 |
| Tyler Brous | Director | 238,088 |
| Carrie Brownstein | Director | – |
| Michael Stewart Lee | Director | – |
| Amy Kate Sasser | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Schreiber | $1.53M | $3.35M | $908.04K | $51 | – |
| FY2024 Dr. Schreiber | $3.22M | $1.08M | $1.95M | $17 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 40 full-time employees at two locations in the United States, in Austin, TX and Durham, NC.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 13, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 5, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |